CEPHALEXIN - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for cephalexin and what is the scope of patent protection?
Cephalexin
is the generic ingredient in five branded drugs marketed by Ajenat Pharms, Alkem Labs Ltd, Anda Repository, Apothecon, Aurobindo Pharma, Barr, Chartwell Rx, Facta Farma, Hikma, Ivax Sub Teva Pharms, Lupin, Purepac Pharm, Stevens J, Sun Pharm Inds (in), Sun Pharm Inds Ltd, Teva, Yoshitomi, Pragma, Hikma Pharms, Vitarine, Yung Shin Pharm, Ranbaxy Labs Ltd, Aurobindo Pharma Ltd, and Lilly, and is included in fifty-eight NDAs. Additional information is available in the individual branded drug profile pages.There are twenty-nine drug master file entries for cephalexin. Thirty-six suppliers are listed for this compound.
Summary for CEPHALEXIN
| US Patents: | 0 |
| Tradenames: | 5 |
| Applicants: | 24 |
| NDAs: | 58 |
| Drug Master File Entries: | 29 |
| Finished Product Suppliers / Packagers: | 36 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Clinical Trials: | 66 |
| Drug Prices: | Drug price trends for CEPHALEXIN |
| Drug Sales Revenues: | Drug sales revenues for CEPHALEXIN |
| What excipients (inactive ingredients) are in CEPHALEXIN? | CEPHALEXIN excipients list |
| DailyMed Link: | CEPHALEXIN at DailyMed |
Recent Clinical Trials for CEPHALEXIN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Aleksi Tornio | PHASE1 |
| Turku University Hospital | PHASE1 |
| University of Turku | PHASE1 |
Pharmacology for CEPHALEXIN
| Drug Class | Cephalosporin Antibacterial |
Medical Subject Heading (MeSH) Categories for CEPHALEXIN
US Patents and Regulatory Information for CEPHALEXIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apothecon | CEPHALEXIN | cephalexin | CAPSULE;ORAL | 062974-001 | Nov 23, 1988 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Hikma Pharms | CEPHALEXIN | cephalexin | FOR SUSPENSION;ORAL | 065444-001 | Aug 28, 2009 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Aurobindo Pharma | CEPHALEXIN | cephalexin | CAPSULE;ORAL | 065253-001 | Nov 16, 2005 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Pragma | KEFLEX | cephalexin | FOR SUSPENSION;ORAL | 050406-002 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch